GLP-1 Drugs Show Promise in Preventing Addictions in Veterans

A new study has revealed that GLP-1 drugs, commonly used to treat diabetes, can significantly reduce the risk of developing new substance use disorders and alleviate existing addictions among U.S. military veterans. The research, led by Dr. Ziyad Al-Aly of the VA Saint Louis Health Care System, indicates that these medications, including Ozempic and Mounjaro, may offer protective effects against a range of addictive substances such as alcohol, opioids, cocaine, nicotine, and cannabis.

The findings, published in The BMJ, were drawn from an analysis of data from the U.S. Veterans Affairs database. The study involved 124,001 veterans with type 2 diabetes who were treated with GLP-1 drugs, compared to 400,816 similar patients prescribed SGLT-2 inhibitors. Over a three-year period, veterans taking GLP-1 medications exhibited a 14% lower likelihood of developing new substance use disorders.

Significant Reductions in Addiction Risks

The study highlighted specific reductions in various substance-related disorders among those on GLP-1 therapy. The odds of developing new alcohol use disorders decreased by 18%, while cannabis use disorders fell by 14%. Cocaine and nicotine use were reduced by 20% and 26%, respectively, and opioid use disorders dropped by 25%. For veterans already struggling with substance use disorders, those on GLP-1 drugs experienced a 31% reduction in emergency department visits related to these issues.

The study also found that GLP-1 medications led to a 26% reduction in related hospital admissions, a 50% decrease in substance-related deaths, and a 39% reduction in drug overdoses. Additionally, the likelihood of suicidal ideation or attempts decreased by 25% among participants using GLP-1 drugs.

Understanding the Mechanism Behind the Findings

Dr. Al-Aly emphasized the study’s unexpected breadth, noting that no single drug has previously shown effectiveness across such a wide variety of addictive substances. He suggested the presence of a common biological pathway that GLP-1 drugs target, potentially offering a new approach to addiction treatment.

The GLP-1 receptors, which interact with these medications, are located in the mesolimbic system of the brain, a region associated with motivation and reward. Dr. Al-Aly explained that GLP-1 drugs may modulate cravings by “silencing the noise” in the brain that often drives individuals toward substance overuse.

While the results are promising, the researchers caution that it remains uncertain whether these benefits will persist over extended periods of medication use. Dr. Al-Aly expressed a desire to further investigate the long-term effects of GLP-1 therapy on addiction.

The VA is planning a comprehensive clinical trial to evaluate the efficacy of semaglutide, a key component of Ozempic and Wegovy, in veterans diagnosed with alcohol use disorder.

In an accompanying editorial, Fares Qeadan of Loyola University highlighted the importance of considering the potential benefits of GLP-1 receptor agonists for individuals with type 2 diabetes who are also at risk for substance use disorders. He urged clinicians to factor these findings into shared decision-making processes regarding treatment options.

As research into GLP-1 medications continues, the implications for addiction treatment could be significant, opening new pathways for addressing substance use disorders among vulnerable populations.